Asfotase alfa (ENB-0040), a bone-targeted genetically engineered glycoprotein, enhances survival, bone mineralization, and growth while preventing mineralization defects in the feet, rib cage, lower limbs, and jaws of Akp2 −/− knockout mice. It has applications in researching perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) [1].

Asfotase alfa (0.5-8.2 mg/kg; s.c. 每日一次，连续43天) 显示出剂量-反应关系，这强烈支持其对HPP [1] 的药理学效能。